Patents by Inventor TROY E. MESSICK

TROY E. MESSICK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EBNA1 Inhibitor Crystalline Forms, and Methods of Preparing and Using Same
    Publication number: 20230103362
    Abstract: The invention relates, in certain aspects, to developable forms of certain compounds that are useful to treat and/or prevent EBV infection and related conditions in a subject. The invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
    Type: Application
    Filed: August 26, 2022
    Publication date: April 6, 2023
    Inventors: TROY E. MESSICK, PAUL M. LIEBERMAN, GARRY R. SMITH, ARLINDO L. CASTELHANO
  • EBNA1 Inhibitor Crystalline Forms, and Methods of Preparing and Using Same
    Publication number: 20190352285
    Abstract: The invention relates, in certain aspects, to developable forms of certain compounds that are useful to treat and/or prevent EBV infection and related conditions in a subject. The invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
    Type: Application
    Filed: May 16, 2019
    Publication date: November 21, 2019
    Inventors: TROY E. MESSICK, PAUL M. LIEBERMAN, GARRY R. SMITH, ARLINDO L. CASTELHANO
  • EBNA1 INHIBITORS AND THEIR METHOD OF USE
    Publication number: 20180086699
    Abstract: Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
    Type: Application
    Filed: November 16, 2017
    Publication date: March 29, 2018
    Inventors: TROY E. MESSICK, GARRY R. SMITH, ALLEN B. REITZ, PAUL M. LIEBERMAN, MARK E. McDONNELL, YAN ZHANG, VENKATA VELVADAPU
  • EBNA1 INHIBITORS AND THEIR METHOD OF USE
    Publication number: 20160289185
    Abstract: The invention provides EBNA1 inhibitors, and pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The compounds and compositions of the invention are further useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. The compounds and compositions of the invention are further useful for the treatment of diseases caused by lytic EBV infection.
    Type: Application
    Filed: November 14, 2014
    Publication date: October 6, 2016
    Inventors: TROY E. MESSICK, GARRY R. SMITH, ALLEN B. REITZ, PAUL M. LIEBERMAN, MARK E. McDONNELL, YAN ZHANG, VENKATA VELVADAPU